TransCode Therapeutics Surges On Positive Preclinical Trial Results

Key points:
TransCode Therapeutics reported positive preclinical results for TTX-MC138
The company evaluated the bioactivity of the drug
TransCode Shares surged premarket

TransCode Therapeutics (NASDAQ: RNAZ) shares have surged to levels last seen in August after the company reported positive preclinical results for its lead candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

TransCode’s stock price is trading 37.5% higher premarket at $1.49 per share, pushing up from its recent lows. The company’s shares have fallen over 61% in the last 12 months and more than 57% in 2022.

Scientist in a lab

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Also Read: The Best Biotech Penny Stocks under $5 to Buy Right Now

The company revealed Tuesday that it evaluated the bioactivity of TTX-MC138 in a “murine model of pancreatic adenocarcinoma.”

The study saw mice, carrying human pancreatic tumors implanted in their pancreas, treated once weekly for 10 weeks with TTX-MC138. The drug was said to have demonstrated a pharmacodynamic response by successfully inhibiting its target.

The company added that 40% of animals treated with TTX-MC138 had complete responses, and further studies to better find the ideal dose and therapeutic window in pancreatic cancer are ongoing.

TransCode co-founder and CTO Zdravka Medarova said the data supports the “advancement of TTX-MC138 into the clinic.”

Michael Dudley, the company’s co-founder, president and CEO, commented: “Demonstrating successful treatment using our first-in-class RNA-targeted therapeutic candidate in a variety of solid tumor models is an important step in the preclinical development process and, we believe, further de-risks our approach,”

“As we have previously indicated, we are on track to submit an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 first-in-human (FIH) clinical trial with TTX-MC138 in cancer patients with advanced solid tumors.”